Endogenous Catecholamines in Immune Cells: Discovery, Functions And Clinical Potential as Therapeutic Targets
The IL-6 Inhibitors Tocilizumab and Sarilumab and COVID-19 Treatment: Controversies but Potential Efficacy in Severe Cases
Brainimmune is Looking for a Strategic Partner to Advance the Neuroendocrine Immunology and Stress-Immunity Research Field
Donna Jackson Nakazawa and Her New Book, THE ANGEL AND THE ASSASSIN: The Tiny Brain Cell that Changed the Course of Medicine
Cognitive Decline and Alzheimer’s Linked to Low Systemic REST Levels and Deficient Stress Protection of the Aging Brain
Encouraging Results from Phase 2a COVID-19 Clinical Trial with the Oral Direct-Acting Antiviral MolnupiravirJuly 7, 2021
New evidence linking platelet-activating anti-PF4 antibodies to the vaccine-induced immune thrombotic thrombocytopeniaApril 19, 2021
Identification of GM-SCF as possible distinctive blood marker predicting severe COVID-19March 23, 2021
Monogenic immune defects in type I interferon pathways as a risk factor for severe COVID-19 pneumoniaJanuary 29, 2021
FDA Authorizes an Emergency Use for Bamlanivimab – an Investigational Monoclonal Antibody – for the Treatment of Mild to Moderate COVID-19November 11, 2020
High Affinity Human Antibody Component Identified as a Potential Targeted SARS-Cov-2 TherapyNovember 3, 2020
NIH begins the first large randomized controlled trial of the combination of interferon beta-1a and remdesivir for treating COVID-19August 13, 2020
The European Commission Approves Remdesivir for the Treatment of Severe Cases of COVID-19July 4, 2020
